Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Data Continue to Illustrate Potential Role of Partial Breast Irradiation in Early-Stage Breast Cancer

April 24th 2024

Robert W. Mutter, MD, discusses research involving partial breast irradiation and multi-modality therapy in early-stage breast cancer.

Health Canada Green Lights Subcutaneous Atezolizumab for Lung, Breast, and Liver Cancer

April 23rd 2024

Health Canada has approved subcutaneous atezolizumab for use in patients with lung cancer, breast cancer, and hepatocellular carcinoma.

Dr Nanda on the Evolution of Treatment For HER2-Low Breast Cancer

April 23rd 2024

Rita Nanda, MD, discusses the evolution of treatment options for patients with HER2-low breast cancer.

Contralateral Breast Cancer Treatment With Germline Mutation Carriers

April 22nd 2024

Siddartha Yadav, MD, FACP, of Mayo Clinic, discusses personalizing treatment for patients with germline–mutant contralateral breast cancer.

Dr Chen on the Investigation of CDK4/6 Inhibitors in Early-Stage Breast Cancer

April 18th 2024

Nan Chen, MD, discusses the investigation of CDK4/6 inhibitors in early-stage breast cancer.

FDA Approves Lumisight and Lumicell DVS for Residual Breast Cancer Detection

April 18th 2024

The FDA has approved the optical imaging agent Lumisight and the Lumicell Direct Visualization System for use in fluorescence imaging in breast cancer.

The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer

April 17th 2024

Medical experts analyze the impact of CDK4/6 inhibitors in early-stage HR+/Her2- breast cancer patients, and how recent clinical trial data translates to the real-world clinical application of these agents.

Dr Gatti-Mays on the Use of Neoadjuvant Chemoimmunotherapy in Early-Stage TNBC

April 16th 2024

Margaret E. Gatti-Mays, MD, MPH, FACP, discusses the current use of neoadjuvant chemoimmunotherapy in early-stage triple-negative breast cancer.

Examining the Evolution of Treatment With CDK4/6 Inhibitors in Metastatic Breast Cancer

April 12th 2024

Anne Favret, MD discusses the FDA approval of capivasertib plus fulvestrant for hormone receptor–positive, HER2-negative breast cancer.

FDA Receives Type C Meeting Request for Pelareorep in HR+/HER2– Metastatic Breast Cancer

April 12th 2024

The FDA has received a type C meeting request from Oncolytics Biotech to discuss a registration-enabling trial for pelareorep in HR+/HER2– breast cancer.

Dr Park on the Assessment of Robot-Assisted Nipple Sparing Mastectomy in Breast Cancer

April 12th 2024

Ko Un “Clara” Park, MD discusses the assessment of robot-assisted nipple sparing mastectomy in breast cancer.

Dr Cobain on Second- and Later-Line Treatment Options in HR+/HER2– Breast Cancer

April 12th 2024

Erin Frances Cobain, MD, on second-line treatment options for patients with HR-positive, HER2-negative metastatic breast cancer.

5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer

April 10th 2024

Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, provide an in-depth analysis of the randomized phase III monarchE trial, which focused on Abemaciclib in high-risk early-stage HR+, HER2- breast cancer, offering insights into recurrence rates, progression-free survival, and distant disease-free survival outcomes for patients.

Olaparib With Chemotherapy Does Not Elicit Improved Outcomes vs Chemotherapy Alone in BRCA Wild-Type TNBC

April 8th 2024

Olaparib on a gap schedule with chemotherapy does not improve responses vs chemotherapy alone in the neoadjuvant setting for patients with BRCA wild-type TNBC.

Saruparib Generates Early Efficacy and Safety Signals in HRR-Mutant Advanced Breast Cancer

April 8th 2024

Saruparib's favorable activity and safety may allow patients with advanced solid tumors to stay on treatment longer vs other approved PARP inhibitors.

Dr Arteaga on CDK4/6 Inhibitor Resistance in ER+ Breast Cancer

April 3rd 2024

Carlos Arteaga, MD, discusses the resistance to CDK4/6 inhibitors in estrogen receptor–positive breast cancer.

NCCN Guidelines vs Real-World Practice: Risk Stratifying HR+/HER2- Early Breast Cancer

April 3rd 2024

Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, examine the NCCN guidelines compared to real-world evidence, particularly in the treatment of menopausal, pre-menopausal, and high-risk early-stage HR+/HER2- patients.

A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2- Positive Metastatic Breast Cancer With Brain Metastases (BMs) from DESTINY-Breast01, -02, and -03

April 2nd 2024

Sara Tolaney, MD, MPH, presents an exploratory pooled analysis of efficacy and safety data of trastuzumab deruxtecan vs comparator in patients with HER2-positive metastatic breast cancer and brain metastases from DESTINY-Breast01, -02, and -03.

FDA Accepts BLA for Datopotamab Deruxtecan for Pretreated HR+/HER2– Metastatic Breast Cancer

April 2nd 2024

The FDA has accepted a biologics license application for datopotamab deruxtecan in HR-positive, HER2-negative metastatic breast cancer.

Dr Mahtani on Addressing Unmet Needs in Breast Cancer

April 1st 2024

Reshma L. Mahtani, DO, discusses how attempts to address unmet needs in breast cancer have evolved over time.